Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) has shared an update.
Circio Holding ASA announced recent in vivo results validating its circVec platform using novel AAV and DNA vector formats, demonstrating enhanced tissue expression profiles compared to conventional mRNA-based vectors. These findings suggest significant potential for circVec in advancing tissue-targeted gene therapy and in vivo cell therapy, positioning the company as a leader in this rapidly evolving field. Additionally, CEO Dr. Erik D Wiklund will provide a corporate update and discuss business development activities at the upcoming annual general meeting.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in circular RNA technology for next-generation nucleic acid medicine. The company focuses on developing innovative solutions for gene and cell therapy, leveraging its circVec platform to enhance tissue-targeted applications.
Average Trading Volume: 1,191,202
Current Market Cap: NOK58.65M
See more insights into 0RIS stock on TipRanks’ Stock Analysis page.